*Disclaimer: As of September 29, 2023, NeuroMend no longer offers Spravato treatments. We apologize for any inconvenience and encourage you to consult with our team or your healthcare provider for alternative options.
We have been working hard at getting back to our customers during this harsh COVID-19 season. And we are excited to be opening our clinic back up with a brand new treatment offering!
Keep reading to discover the latest news around Neuromend's REMS Spravato certification!
NeuroMend Infusion Center is now a Risk Evaluation and Mitigation Strategy (REMS) facility certified to provide SPRAVATO™ (esketamine), a nasal spray approved for use in conjunction with an oral antidepressant in adults with treatment-resistant depression (TRD).
People who are currently struggling with major depressive disorder (MDD) may have TRD if they have not responded adequately to at least two different antidepressants of adequate dose and duration in the current depressive episode.2
SPRAVATO™ was approved by the U.S. Food & Drug Administration (FDA) on March 5, 2019, and is only available to patients at REMS–certified treatment centers in the United States.
We recently publish a blog that dives into everything you need to know about Spravato treatments.
But, for brevity purposes in this blog, SPRAVATO™ is a prescription medicine, used along with an antidepressant taken by mouth, for treatment-resistant depression (TRD) in adults.
Many patients are finding relief from treatment resistant depression by utilizing Ketamine to improve their symptoms.
Now with the FDA approved form of Ketamine (Spravato or Esketamine) hitting the market, many consumers are curious about the difference between the two.
Read more to see which option will be best for your treatment.
The official acronym "REMS" stands for "Risk Evaluation and Mitigation Strategy".
NeuroMend Infusion Center is now certified in Risk Evaluation and Mitigation Strategy (REMS) to provide SPRAVATO™ (esketamine) to patients with treatment resistant depression.
If you or someone you know is interested in learning more about SPRAVATO™ and see if it can help them with their treatment resistant depression, click below to learn everything you need to know about SPRAVATO™. It just may be the answer they have been looking for.
Contact our experienced staff today if you have any questions.
*Disclaimer: As of September 29, 2023, NeuroMend no longer offers Spravato treatments. We apologize for any inconvenience and encourage you to consult with our team or your healthcare provider for alternative options.
We Provide Effective Treatment For The Following Conditions: Major Depressive Disorders, Post-traumatic Stress Disorder (PTSD), Bipolar Depression, Obsessive Compulsive Disorder (OCD), Chronic Migraines, Severe Anxiety, Fibromyalgia and Chronic Pain Syndromes.